of the planned 64 subjects had undertaken testing due to concerns regarding adverse events. Severe adverse events were experienced in 0/6 (0%) in the placebo group, 0/12 (0%) in the alcohol group, 4/10 (40%) in the party pill group and 3/7 (43%) in the combined party pill and alcohol group. The severe adverse events included agitation, anxiety, hallucinations, vomiting and migraine. Party pills, alone and in combination with alcohol, markedly increased blood pressure, although had no significant effect on QTc interval or body temperature. Party pills alone improved driving performance at 6.5 hours after dosing. We conclude that party pills commonly cause severe adverse reactions and have marked cardiovascular effects when taken in similar doses to those recommended by manufacturers.
Abstract
Party pills containing benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) are used as recreational drugs for their stimulant effects. An estimated 20 million doses of these party pills have been sold legally in New Zealand over the past six years. There is a significant gap in the research on the clinical effects of BZP and TFMPP, with only two small clinical trials on BZP published in the 1970s, and no clinical trials on TFMPP. This situation led to the Expert Advisory Committee on Drugs (EACD) recommendation that more information on the effects of BZP and TFMPP should be obtained. We conducted a randomised double blind placebo controlled trial which assessed the effects of BZP/TFMPP alone and in combination with alcohol (six standard units). The doses of BZP/TFMPP (300mg/74mg over a two hour period) were based on those recommended by the party pill industry. The six units of alcohol given was the maximum dose recommended by ALAC to be taken in a session. Cardiovascular parameters, psychological functioning, driving performance and delayed effects on sleep and mood were assessed. The study was stopped after 35 of the planned 64 subjects had undertaken testing due to concerns regarding adverse events. Severe adverse events were experienced in 0/6 (0%) in the placebo group, 0/12 (0%) in the alcohol group, 4/10 (40%) in the party pill group and 3/7 (43%) in the combined party pill and alcohol group. The severe adverse events included agitation, anxiety, hallucinations, vomiting and migraine. Party pills, alone and in combination with alcohol, markedly increased blood pressure, although had no significant effect on QTc interval or body temperature. Party pills alone improved driving performance at 6.5 hours after dosing. We conclude that party pills commonly cause severe adverse reactions and have marked cardiovascular effects when taken in similar doses to those recommended by manufacturers.
Background
Party pills, also known as "herbal highs" or "social tonics", have become increasingly popular in New Zealand since their introduction in 1999, with more than 20 million 1 doses reportedly sold in the past six years. These pills, which contain BZP often in combination with TFMPP as their main active ingredients, are used for their stimulant 2 and euphoric effects. They remain legal in New Zealand because the Expert Advisory Committee on Drugs (EACD) found there was insufficient evidence to make a BZP and TFMPP are members of the piperazine group of chemically synthesized 7 compounds, along with other well-known examples such as cyclizine and sildenafil. 6 BZP was originally synthesized in 1944 as a potential antiparasitic agent, and subsequently found to reverse the effects of tetrabenazine (a dopamine depleting drug) 8 in rats and mice, indicating potential antidepressant activity. Two clinical trials were conducted in the 1970s to establish the clinical effects of BZP in humans prior to 9 proceeding with clinical trials in depressed patients. These trials found that BZP has cardiovascular and central nervous system effects similar to dexamphetamine. 
Method
The study was a randomised double blind placebo-controlled trial. It was approved by the Central Regional Ethics Committee. Recruitment was through newspaper advertising, posters at the local university campus and Cosmic Corner party pill retail outlet and through word of mouth. Study volunteers gave written informed consent before undergoing any tests and were reimbursed for their involvement in the study.
Subjects
Inclusion criteria: All subjects were 20 years of age or older. They had previously taken party pill containing BZP and/or TFMPP on three or more occasions without serious adverse reactions such as seizures or other toxic effects requiring medical attention. They had a valid New Zealand drivers licence. Use of alcohol was also a pre requisite.
Exclusion criteria: Subjects with a history of diagnosed psychiatric conditions, epilepsy, moderate to severe asthma, hypertension (BP >150/95 at first hospital visit), glaucoma, thyroid disorders, diabetes, urinary difficulties, cardiovascular disease or lactose intolerance were excluded. Those using any medication with an effect on serotonin or dopamine were excluded.
Doses and administration
The BZP/TFMPP study capsules were derived from the contents of two Jet and two minutes. Subjects were fasted prior to and during medication dosing.
Study procedures
A preliminary visit to the hospital-based research unit took place, at which time full explanation of the study was provided. Informed consent was gained as were details of a responsible adult aged over 20 years who would act as a support person for the subject on their test day. A computer-based questionnaire on previous party pill and alcohol use, driving history and sensation seeking tendencies was performed. The DSM-IV criteria for substance dependence was used in a computerised format to determine 34 which subjects displayed signs of a substance use disorder. test. Three training runs were completed to familiarise subjects with the simulator controls and tasks, namely the divided attention and car following tasks, and then the twelve minute driving test was performed with standardised instructions.
The clinical investigator contacted the nominated support person, explained the study in detail to them, and gained their written undertaking to act as support person for the subject on his or her test day. The role of the support person was to be aware of potential risks or side effects of the study and to support and monitor the subject for the presence of side effects as necessary. Both the subject and the support person were provided with written information regarding who to contact should any medical emergency or complications occur.
Subjects were advised to avoid the use of any recreational drugs from one week before until one week after the test day, to avoid the use of alcohol from 8pm the night before the test day, and to fast from food for a minimum of six hours before the start of their test day.
Subjects attended the research unit for a twelve hour test day, during which time caffeine and nicotine use was not permitted. Compliance and consent were reviewed at the start of the day, and weight and height measured. Urine was tested using the One
Step Multi-Drug Multi-Line Screen Test for the presence of amphetamine, barbiturates, benzodiazepines, cocaine, marijuana, methadone, methamphetamine, MDMA, opiates, phencyclidine, and tricyclic antidepressants. An indwelling intravenous cannula was inserted and blood samples taken.
Measures
Driving performance was assessed using a twelve-minute test on the STISIM driving simulator. The simulator displays a realistic driving scenario similar to driving along a straight piece of open road. The three training scenarios were repeated on the test day, prior to the baseline driving test. The driving test comprised three sections:
1) accelerating up to and following a car at a consistent distance (taught in the training scenarios)
2) completing divided attention tasks (use of indicators and horn according to symbols displayed on screen) while following another car
3) continuing to complete divided attention tasks while maintaining the speed limit Subjects were given standardised instructions. They were asked to drive at the correct speed limit (unless following a car which should be done at the correct distance), indicate or press the horn immediately when the divided attention prompt appeared, and try to stay in the middle of the left lane. The primary outcome variable was the Standard Deviation of Lateral Position (SDLP) from the third section of the driving test (road tracking). SDLP measures the ability of the driver to control weaving of the car 37 and has been shown to be a sensitive indicator of drug-induced driving impairment.
A self-reported evaluation of intoxication, driving safety and degree of sleepiness was made before and after each driving test. A standardised clinical sobriety test was performed after the first three driving tests.
The vital signs including heart rate, systolic and diastolic blood pressure and temperature were recorded two hourly for ten hours. An electrocardiograph (ECG) was taken just prior to the 3.5 hour and 6.5 hour blood test. The QTc interval was chosen as the key electrophysiological outcome variable. Subjects reported whether acute side effects had occurred with previous party pill use in a computerised questionnaire. A list of 32 previously reported adverse effects from party pill use was displayed, and subjects asked to state whether these effects had occurred previously or never.
Information on adverse effects relating to the study intervention was collected in two ways. Ten hours after dose ingestion, subjects reported whether they had experienced any of a shown computerised list of acute side effects on the test day, and if so, if they rated the symptom as severe or not. They reported delayed side effects during a structured interview at a follow-up visit one week after the test day. The severity of adverse events was rated according to the standardised definitions of Clinical Research [41] [42] [43] Adverse Events, with the modification that any event rated by the subject as "severe" was included as a severe event:
Mild -awareness of sign or symptom, but easily tolerated Moderate -marked symptoms, discomfort enough to cause interference with usual activity Severe -incapacitating with inability to work or perform usual activity; rated by subject as severe.
Sleep diaries were given to each subject at the end of the test day for completion over the following seven days. Each subject was asked to report the hours and times slept each night for seven nights, the number of minutes taken to fall asleep, and to rate their Sleep diaries and questionnaires were returned at the follow-up meeting seven days after the test day. At this time, a repeat Profile of Mood States for the previous week was performed, and the subjects gave feedback regarding any problems experienced since the test day.
The sequence of testing performed on the test day is shown in Table 1 , with the time in hours after dose administration shown for each test. Meals were provided at four and seven hours after drug administration. 
Statistical analysis
The trial utilised a randomised factorial design. Analysis was by a general linear model.
An interaction term was tested and if not statistically significant for a response variable it was omitted from the model and main effects only fitted for alcohol and BZP/TFMPP.
For the driving variable a baseline effect was also fitted. Although descriptive statistics are presented for each factorial combination of treatments this is for illustrative purposes only.
When the interaction term was not significant it is not statistically valid to test, for example, a particular factorial combination such as BZP/TFMPP alone versus placebo alone, or alcohol alone versus BZP/TFMPP alone. In the case where the interaction term was not statistically significant then the main effects are independent and represent alcohol versus not using alcohol and BZP/TFMPP versus not using BZP/TFMPP.
Normality assumptions were met for analyses. SAS version 9.1 was used for the analysis.
Results

Pill composition and dose selection
The dose of BZP and TFMPP included in the commercial and study capsules is shown in 
Baseline characteristics
The characteristics of the 35 subjects who completed the study are shown in Table 3 .
Most subjects were male, aged between 20 and 30 years, in paid employment and identified as being New Zealand Europeans. Their average Body Mass Index (BMI) of 2 2 45 26.4 kg/m lies just above the normal healthy range for adults (18.5-24.9 kg/m ).
Results from baseline urine drug screening on the test day confirmed that 32 of the 35 subjects tested negative for the presence of recreational drugs. Three subjects were positive for cannabis, and were included in the trial because they reported there had been no cannabis use in the week prior to the test day, recognising that cannabinoid 46 urinary metabolites can be detected up to 77 days after chronic use. 
Party pill use
The patterns of party pill use by the subjects included in the study are shown in Table 4 .
Most subjects had used party pills five or more times prior to the study. Most did not know the active ingredients of the party pills typically taken. Of those who did know what ingredients were contained in party pills, most used a BZP/TFMPP combination pill (9 out of 11). Using the standard DSM-IV criteria, about a fifth of the subjects showed patterns of psychological dependence on party pills. Physiological dependence, as determined by the presence of tolerance or withdrawal symptoms, was present in six out of the group of 35. DSM-IV criteria: Party pill psychological dependence, n=33 † 6 (18.2) Party pill physiological dependence (i.e. tolerance 6 (17.1) or withdrawal present) † Data on this parameter was missing for one subject † Data on this parameter was missing for two subjects In terms of previous use, subjects took up to five party pills on a typical occasion. A maximum of 14 pills were taken on a single occasion (Table 5) .
Table 5 -Number of party pills taken by subjects
Median
Min Max
Number of party pills used on a typical occasion 2 1 5
Largest number of pills taken on one occasion
The most popular party pills reportedly used by our subjects were Charge, Jet, Bliss, Kandi, Rapture, Frenzy and the Grunter. Recommended consumption and maximum doses of these varieties are summarised in Table 6 . The recommended maximum dose of BZP in this group of party pills ranged from 100 to 360mg combined with TFMPP doses ranging from 0 to 100mg. 
Alcohol use
The patterns of alcohol use by the subjects included in the study are shown in Table 7 .
Most subjects were drinking alcohol when they first tried party pills. The vast majority reported using party pills with alcohol some, most or all of the time. About two in three 33 subjects had a pattern of high risk drinking as defined by ALAC. About one in four subjects had alcohol dependency by DSM-IV criteria. .2) Alcohol physiological dependence (i.e. tolerance or 13 (37.1) withdrawal present) † Data on these parameters was missing for one subject † Data on this parameter was missing for two subjects
Blood concentrations of BZP, TFMPP and alcohol
The blood levels of BZP, TFMPP and alcohol are shown in Figures 1, 2 and 3 respectively. The levels of BZP and TFMPP peaked at 6.5 hours at mean values of 585ng/ml and 41ng/ml respectively. Alcohol levels dropped sharply after reaching their peak mean value of 36mg/100ml at 3.5 hours. 
Previous adverse events
The proportion of subjects reporting specific acute adverse events with previous party pill use is shown in Figure 4 . The most commonly reported side effects from previous party pill use were dry mouth, nose and throat, loss of appetite, headache, feeling cold, sweatiness and nausea -all experienced by over half of the group. Palpitations, increased libido, facial flushing and anxiety were the next most commonly reported effects. 
Study adverse events
An interim safety analysis was undertaken after 35 subjects had completed the investigative modules, due to concerns about the frequency, nature and severity of the acute (test day) and delayed (one week) side effects that were being reported. The nature and intensity of the adverse events is shown in Table 8 . At this stage, the treatment allocation was placebo (n=6), alcohol (n=12), BZP/TFMPP (n=10), and alcohol and BZP/TFMPP (n=7). There were 4/10 and 3/7 severe adverse events reported in the BZP/TFMPP and BZP/TFMPP & Alcohol groups; no severe events were reported in the Placebo or Alcohol only groups. Together there were 7/17 (41%) severe adverse reactions in the BZP/TFMPP groups (with and without alcohol) and 0/18 (0%)
severe adverse reactions in the non-BZP/TFMPP groups. Of those who had severe reactions, the mean (±SD) 6.5 hour blood levels of BZP and TFMPP were 570 (± 117) ng/ml and 43 (±31) ng/ml respectively compared with 593 (± 134) ng/ml and 40 (±18) ng/ml respectively in the subjects receiving BZP and TFMPP who had mild or no adverse reactions.
Due to the frequency and nature (agitation, anxiety, hallucinations, confusion, vomiting, insomnia, headaches and migraine) of the severe reactions, a decision was made to stop the study after 35 subjects had completed the testing. 
Physiological parameters
The effect of the different treatments on cardiovascular measures and body temperature is shown in Table 10 with the statistical significance of the differences shown in Table   11 . BZP/TFMPP significantly raised the systolic and diastolic blood pressure.
BZP/TFMPP was weakly associated with a faster heart rate and higher body temperature. Alcohol had no detectable effect on blood pressure or heart rate but was associated with a lower body temperature. There was no significant effect of any treatment on the QTc interval. Across the physiological variables including driving performance, cardiovascular function, body temperature and sleep, there was no interaction between alcohol and BZP/TFMPP suggesting that the physiological effects of the two treatments are independent. As the trial was stopped early there was likely to be low statistical power for comparisons, as shown with the wide confidence intervals for the comparisons that were performed. Some caution must be exercised in interpretation of statistically significant P values as multiple statistical testing has been carried out and this raises the possibility that some of the 'significant' tests are significant by chance alone.
Comment
The study has shown that BZP/TFMPP combination party pills, taken both alone and/or with alcohol, result in a high rate of severe adverse reactions. The nature, frequency and severity of the adverse reactions due to BZP/TFMPP were sufficient to require the premature cessation of the study. The adverse reactions occurred when BZP and TFMPP were given in quantities recommended and frequently consumed in the community as recreational drugs.
There are a number of methodological issues relevant to the interpretation of this study's findings.
Firstly, the study utilized a randomised double-blind placebo controlled design, and as a result the findings provide Level A evidence. Importantly, the reporting and documentation of the side effects was undertaken blind, by both the subject and investigator.
The cumulative dose of the dihydrochloride forms of BZP and TFMPP was 300mg and 74mg respectively. These doses were based on the recommended doses of BZP and TFMPP stated on the labels of the commercially available products of between 100mg
and 360mg, and 20mg and 100mg respectively. The dose administered was also well within the range of doses normally taken. For example, our subjects took up to five pills on a typical occasion and up to 14 pills as a maximum. This is similar to that reported in other New Zealand surveys, in which 4 out of 10 users took four or more pills on one occasion and the maximum taken was up to 19. 28, 29 As a result the findings of major side effects relate to doses typically taken by users of party pills.
Similarly the amount of alcohol administered was that recommended by ALAC as the 33 maximum to be consumed on one occasion. A total of six units of vodka (mixed in orange juice) taken over a three hour period, was designed to achieve a blood alcohol level between the legal level for a driver under 20 years (30mg/dl) but below the drink 47 drive level for adults of 80mg/dl. This was achieved, with a mean alcohol level of 36mg/dl in subjects randomised to alcohol.
The study drugs were administered in the morning, rather than in the evening when they are usually taken recreationally. This regime was followed to allow 10 hours of detailed investigations and observation, but probably meant that the recognized effects of party pills in causing insomnia were less marked than if the pills were taken in the evening.
The adverse effects resulting from BZP/TFMPP use were severe and posed a significant potential risk to subjects. In one case, the anxiety which occurred on the test day prevented the subject from completing the driving or blood tests. The potential risk associated with the insomnia caused by party pills was illustrated in one of our subjects who drove the day after dose administration having had no sleep whatsoever the night before. The severe acute effects included anxiety, agitation, and hallucinations whereas the delayed effects refer to the insomnia, headache, fatigue and malaise which occurred in the day or two after dose ingestion. The latter are commonly referred to as a "bad 48 hangover" which causes many people to limit their use of party pills.
These adverse effects are similar to those described in the recent Christchurch case 27 series and suggest party pills have a narrow safety margin in some users. This study adds the knowledge that BZP/TFMPP related products can cause serious toxicity including seizures, in doses used and recommended in the community, even in regular party pill users. Interestingly the combination of alcohol with party pills appeared to induce vomiting which was not observed with party pills alone. The vomiting occurred after the completion of the ten-hour period of observation.
The EACD reported in 2004 that there has previously been no evidence of physical 3 dependence on BZP or similar substances. However, our survey showed evidence of tolerance or withdrawal symptoms in about a fifth of subjects. BZP's "non addictiveness" has also been called into question by a recent study showing BZP has an 49 abuse liability similar to amphetamines and cocaine in rhesus monkeys. It is possible that BZP could exert an addictive effect by increasing the endogenous release of dopamine and/or serotonin, the mechanism seen with other similar drugs of misuse such 50 as cocaine, amphetamine and MDMA.
The study included detailed investigation of driving performance, cardiovascular effects, and psychological function as well as sleep quality and patterns during the week following the test day. While the detailed statistical analysis is awaited, a preliminary analysis on the study's primary outcome variables provided important information on these effects.
Party pills caused a marked increase in blood pressure which could increase risk in predisposed individuals. Following BZP/TFMPP, the mean blood pressure increased to 142/85 compared with 121/76 after placebo. The likely mechanism by which BZP and TFMPP cause an increase in blood pressure, and to a lesser extent heart rate, is via noradrenaline release which produces sympathomimetic effects. 9, 10, 12, 13 Other amphetamines, for example methamphethamine and MDMA, have been shown to have similar effects. 51, 52 Gee et al 27 found evidence of a prolonged QTc in 32% of subjects whereas in our study the doses of BZP/TFMPP given did not cause a prolongation of QTc.
The use of BZP/TFMPP improved driving performance is the acute setting. This finding is consistent with previous work on amphetamine, which can improve psychomotor skills, even in combination with alcohol. 53, 54 The fatigue which follows this period of stimulation could however negatively affect driving ability, given that fatigue and sleepiness have been associated with driving impairment. 55, 56 Alcohol had a weak effect on SDLP, an observation which probably relates to the low alcohol level at the time of the 6.5 hour driving assessment.
Despite giving the dose early in the morning in this study, we found that party pills caused greater difficulty in getting to sleep, as shown by a significant decrease in the GTS score. This is comparable to the effect of amphetamine in reducing the GTS 
Conclusion
In conclusion the study has demonstrated that the consumption of the party pills containing BZP/TFMPP either alone or in combination with alcohol in the recommended doses carries the risk of severe adverse effects. A BZP/TFMPP combination may have marked effects on cardiovascular function and sleep. These effects, which are similar to those of MDMA and amphetamine, are likely to be due to neurobiological changes in the central nervous system, particularly linked to dopamine, catecholamine and serotonin transmission. The study findings have personal, community, public health and regulatory implications.
